Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - February 2014

Advances and Progress in Drug Design

17 Feb 2014 - 18 Feb 2014 - London, UK

Bookmark and Share


SMi are proud to present the 13th annual Advances and Progress in Drug Design conference, convening in Central London on Monday 17 and Tuesday 18 February 2014. This exciting event will focus on new approaches and will offer attendees the chance to hear from leading industry experts on lead optimisation strategies, SBDD and FBDD. 

Past events have received positive feedback from the industry including ‘Well selected talks, stimulating atmosphere’ – Sanofi, ‘Very good interactive meeting, overall excellent’ – Pfizer and ‘a very good meeting – right number of people’ - AstraZeneca

Advances and Progress in Drug Design Conference will build on the success of our previous events and bring together a unique mix of senior executives from all over industry and academia and will be an unrivalled forum for problem-solving discussion and debate. 

Benefits of Attending:

Understand pharma's current and future drug design strategies and highlight the challenges the industry is currently facing

Explore the latest approaches in structure-based drug design

Evaluate lead optimisation strategies

Consider the latest in fragment based drug discovery as the future of drug design

Linking HTS and FBDD - examining alternative approaches in drug discovery

Participate in two post conference interactive workshops hosted by Vernalis on New Approaches in ‘Structure Based Design’, and the 2nd hosted by The Research Network on ‘Chemically Modified Biologicals’

Ample opportunity for peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group on end of day one.

Key Speakers for 2014

John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer

Sudharsan Sridharan, Scientist, MedImmune

Tom Heightman, Senior Director, Astex Pharmaceuticals

Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals

Karl-Heinz Baringhaus, Head of R&D, Sanofi-Aventis

Andreas Kuglstatter, Head of Protein Crystallography, Roche Chemische Unternehmungen AG

Dr Neil Press, Director, Novartis

Paul Labute, CEO, Chemical Computing Group

Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics

Paul Brennan, Group Head/PI, Nuffield Department of Medicine

For further information visit us online at

Alternatively, contact John Collins on +44 (0)20 7827 6734 or email

Further information
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos